1. Home
  2. ZVRA vs VSTM Comparison

ZVRA vs VSTM Comparison

Compare ZVRA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$9.81

Market Cap

689.4M

Sector

Health Care

ML Signal

HOLD

VSTM

Verastem Inc.

HOLD

Current Price

$9.90

Market Cap

731.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZVRA
VSTM
Founded
2006
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
689.4M
731.8M
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
ZVRA
VSTM
Price
$9.81
$9.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
10
Target Price
★ $25.00
$17.22
AVG Volume (30 Days)
744.9K
★ 4.5M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 159.21
17.49
EPS
★ 0.74
N/A
Revenue
★ $106,470,000.00
$30,914,000.00
Revenue This Year
$43.97
$260.96
Revenue Next Year
$15.93
$42.64
P/E Ratio
$14.00
★ N/A
Revenue Growth
★ 350.91
209.14
52 Week Low
$8.01
$3.43
52 Week High
$15.04
$10.82

Technical Indicators

Market Signals
Indicator
ZVRA
VSTM
Relative Strength Index (RSI) 36.35 66.38
Support Level $9.29 $5.41
Resistance Level $11.19 N/A
Average True Range (ATR) 0.46 0.86
MACD -0.03 0.17
Stochastic Oscillator 3.61 91.90

Price Performance

Historical Comparison
ZVRA
VSTM

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: